− | Acute myeloid leukemia with myelodysplastic-related changes (AML-MRC) is an acute leukemia with 20% peripheral blood or bone marrow blasts with morphological features of myelodysplasia, or occurring in patients with a prior history of a MDS or MDS/MPN, or with MDS-related cytogenetic abnormalities, in the absence of prior history of cytotoxic or radiation therapy for an unrelated disease, and of recurrent cytogenetic aberrations or genetic abnormalities (mutated NPM1 or biallelic mutation of CEBPA) as described in [[Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities]]. This category has been retained in the 2016 revision to the World Health Organization (WHO) classification system with more refined criteria<ref name=":0">{{Cite journal|last=Arber|first=Daniel A.|last2=Orazi|first2=Attilio|last3=Hasserjian|first3=Robert|last4=Thiele|first4=Jürgen|last5=Borowitz|first5=Michael J.|last6=Le Beau|first6=Michelle M.|last7=Bloomfield|first7=Clara D.|last8=Cazzola|first8=Mario|last9=Vardiman|first9=James W.|date=2016|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|url=https://www.ncbi.nlm.nih.gov/pubmed/27069254|journal=Blood|volume=127|issue=20|pages=2391–2405|doi=10.1182/blood-2016-03-643544|issn=1528-0020|pmid=27069254}}</ref><ref name=":1">Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p160-161.</ref>. | + | Acute myeloid leukemia with myelodysplastic-related changes (AML-MRC) is an acute leukemia with 20% peripheral blood or bone marrow blasts with morphological features of myelodysplasia, or occurring in patients with a prior history of a MDS or MDS/MPN, or with MDS-related cytogenetic abnormalities, in the absence of prior history of cytotoxic or radiation therapy for an unrelated disease, and of recurrent cytogenetic aberrations or genetic abnormalities (mutated NPM1 or biallelic mutation of CEBPA) as described in [[HAEM4:Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities]]. This category has been retained in the 2016 revision to the World Health Organization (WHO) classification system with more refined criteria<ref name=":0">{{Cite journal|last=Arber|first=Daniel A.|last2=Orazi|first2=Attilio|last3=Hasserjian|first3=Robert|last4=Thiele|first4=Jürgen|last5=Borowitz|first5=Michael J.|last6=Le Beau|first6=Michelle M.|last7=Bloomfield|first7=Clara D.|last8=Cazzola|first8=Mario|last9=Vardiman|first9=James W.|date=2016|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|url=https://www.ncbi.nlm.nih.gov/pubmed/27069254|journal=Blood|volume=127|issue=20|pages=2391–2405|doi=10.1182/blood-2016-03-643544|issn=1528-0020|pmid=27069254}}</ref><ref name=":1">Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p160-161.</ref>. |